Cell-mediated immunity to respiratory syncytial virus induced by inactivated vaccine or by infection.
about
Development of next-generation respiratory virus vaccines through targeted modifications to viral immunomodulatory genesInhibitory effects of antiviral compounds on respiratory syncytial virus replication in vitroVbeta14(+) T cells mediate the vaccine-enhanced disease induced by immunization with respiratory syncytial virus (RSV) G glycoprotein but not with formalin-inactivated RSVRespiratory syncytial virus infection: immune response, immunopathogenesis, and treatmentPriming with secreted glycoprotein G of respiratory syncytial virus (RSV) augments interleukin-5 production and tissue eosinophilia after RSV challengeRNA virus reverse genetics and vaccine design.Respiratory syncytial virus vaccinesRespiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV.Immunization of macaques with formalin-inactivated respiratory syncytial virus (RSV) induces interleukin-13-associated hypersensitivity to subsequent RSV infectionCurrent concepts and progress in RSV vaccine development.Biological challenges and technological opportunities for respiratory syncytial virus vaccine development.Progress in understanding and controlling respiratory syncytial virus: still crazy after all these yearsGeneration of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus.Involvement of antibody, complement and cellular immunity in the pathogenesis of enhanced respiratory syncytial virus disease.Novel antigens for RSV vaccines.The extraction of lymphoid cells from the human nasopharynx.Complement fixation and neutralization RS antibodies in maternal and neonatal seraUniversal vaccine against respiratory syncytial virus A and B subtypes.A role for immune complexes in enhanced respiratory syncytial virus disease.Viral and host factors in human respiratory syncytial virus pathogenesis.Immunogenicity and protective efficacy of a dual subunit vaccine against respiratory syncytial virus and influenza virusEnhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10.Detection, pathogenesis, and therapy of respiratory syncytial virus infectionsCharacterization of recombinant respiratory syncytial viruses with the region responsible for type 2 T-cell responses and pulmonary eosinophilia deleted from the attachment (G) protein.Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cellsRespiratory syncytial virus: virology, reverse genetics, and pathogenesis of disease.Cytolytic T-lymphocyte responses to respiratory syncytial virus: effector cell phenotype and target proteins.Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virusRespiratory syncytial virus infection modifies and accelerates pulmonary disease via DC activation and migration.Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine.T cell source of type 1 cytokines determines illness patterns in respiratory syncytial virus-infected mice.Specific human cytotoxic T cells recognize B-cell lines persistently infected with respiratory syncytial virusConserved immunogens in prime-boost strategies for the next-generation HIV-1 vaccines.The CD4 T cell response to respiratory syncytial virus infection.Respiratory syncytial virus infection is associated with an altered innate immunity and a heightened pro-inflammatory response in the lungs of preterm lambs.Immunopathogenesis associated with formaldehyde-inactivated RSV vaccine in preclinical and clinical studies.Immunodominant T-cell epitope on the F protein of respiratory syncytial virus recognized by human lymphocytes.Human cytotoxic T cells stimulated by antigen on dendritic cells recognize the N, SH, F, M, 22K, and 1b proteins of respiratory syncytial virus.Pathogenesis of respiratory syncytial virus vaccine-augmented pathology.Respiratory syncytial virus infections in malnourished children.
P2860
Q26782411-AD5B978F-8AA3-4128-8A8C-4BFC5BAF8FEBQ28361333-DD2CD133-B8B1-4E47-9D4C-DA6DDCB6802FQ30448968-68AB6547-D531-4612-A2B2-D7047B14B199Q33588916-9936D77F-EB2A-4849-8564-AFE619D41B98Q33783066-EA25C2FA-1530-4945-A3BC-2AFDE3A7DEFCQ33963398-F3B1DABB-A6B8-4D60-B49F-342BC892AAE0Q33975330-769DD24A-0201-4334-AF20-26588273CEECQ34151000-A50F51E0-32BC-4D14-BB04-3E732DE95AF3Q34355131-C5513CA8-80B2-4C96-A3F1-4A792C86435CQ34396689-01D037CA-5CE4-4BF2-816A-19F6D4A3FBE2Q34504791-4B3A5E8C-A45F-4CC8-9D5A-7786E7F20AB9Q35566601-7F3FAB24-4C1A-4446-8DFA-E9ADAACDFC5CQ35872191-4B1E03C2-3C76-4831-A874-D58B9B963BA6Q35987805-CF3C24D2-6350-415D-9C13-B545E5508D8EQ36005960-74926CE6-C46A-4E1A-A23B-2CAF8A7A2C7DQ36091678-35A4CE2A-C409-4690-A2CD-C21DE5F3AA36Q36250916-2F506178-4A6B-418F-953E-0AAF1D3845B2Q36338294-DB810F20-B430-4242-8706-3DD41B173992Q36371267-61751868-BAD0-4098-BB6A-DE9633999862Q36483836-B79D661D-B559-48FD-B2BE-8BF9FF484722Q36592781-5D4C68A7-377A-4414-AD65-01579F2F4DA4Q36626174-56F1E914-1D48-4283-A919-CAE03253AC8BQ36632499-17EB02B5-F440-4C5D-81CC-CD9192673734Q36684360-2D533A38-BECC-4CF4-A7F3-A589D9132F19Q36687435-ADFD49F8-0690-4A45-8505-DC42482EC659Q36692791-C4FE38D3-908E-4828-8C96-6A8D51296276Q36782773-B4849ABE-D1F9-4D12-9EC6-FCAA9ECD2E15Q36858777-BD5CAAF9-DAD1-4E85-9CA0-DFA9DE98BB68Q36935746-BA766AA3-4D08-4DC7-8C6D-AF7177CBB550Q37208256-8F4B531A-BD09-42F0-922E-F7963893577AQ37366590-9E890DCF-784C-46C9-AF22-9D6212C8DFB9Q37410108-F3206A0A-D0EF-46B1-B45C-3522C664C619Q38184579-EBCFCEE6-85CC-47FE-A65F-5DC80934A971Q38212550-868C0181-AC8F-4E68-8BF0-4EAF335AFC78Q38365417-08AA30CB-3BC5-4082-B805-56C584E69950Q39007664-77FFDEDD-BCA9-45AD-9E38-A24FCA9CFEC3Q40067229-3749A8DF-9E4E-433D-8C9A-A22F687784BCQ40308643-CFCA039E-F9F0-4D3E-963A-04044A9F6C70Q40408366-D6FE5CF6-3E40-4CA5-8E0C-394364E283C5Q40708887-E54CAE0E-3B61-4D8A-B262-446CB4E14BAB
P2860
Cell-mediated immunity to respiratory syncytial virus induced by inactivated vaccine or by infection.
description
1976 nî lūn-bûn
@nan
1976年の論文
@ja
1976年学术文章
@wuu
1976年学术文章
@zh
1976年学术文章
@zh-cn
1976年学术文章
@zh-hans
1976年学术文章
@zh-my
1976年学术文章
@zh-sg
1976年學術文章
@yue
1976年學術文章
@zh-hant
name
Cell-mediated immunity to resp ...... vated vaccine or by infection.
@en
Cell-mediated immunity to resp ...... vated vaccine or by infection.
@nl
type
label
Cell-mediated immunity to resp ...... vated vaccine or by infection.
@en
Cell-mediated immunity to resp ...... vated vaccine or by infection.
@nl
prefLabel
Cell-mediated immunity to resp ...... vated vaccine or by infection.
@en
Cell-mediated immunity to resp ...... vated vaccine or by infection.
@nl
P2093
P1433
P1476
Cell-mediated immunity to resp ...... vated vaccine or by infection.
@en
P2093
P356
10.1203/00006450-197601000-00015
P407
P577
1976-01-01T00:00:00Z
P5875
P6179
1016027118